Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Even protein Clear all
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 2, 2026, 9:49 AM EDT
Terminated Phase 4 Interventional Results available

The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination

NCT03367429
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botox
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 2, 2026, 9:49 AM EDT
Recruiting Phase 2Phase 3 Interventional

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

NCT05664789
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N acetyl cysteine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 2, 2026, 9:49 AM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT03710772
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Ibrutinib, Methotrexate, Rituximab, Venetoclax, Vincristine Sulfate
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 2, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT00607438
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Sorafenib (Nexavar)
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Sep 2, 2026, 9:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

NCT04165330
View directory record Official record
Conditions
Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
AL3818, Nivolumab Injection
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00038610
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Mesna, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

NCT00002556
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
vincristine sulfate, carmustine, melphalan, cyclophosphamide, prednisone, recombinant interferon alfa-2b, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

NCT01125176
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
thalidomide, lenalidomide, rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 2, 2026, 9:49 AM EDT
Withdrawn Phase 1 Interventional

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

NCT02639767
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI
Drug · Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • East White Plains, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 2, 2026, 9:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

NCT02391545
View directory record Official record
Conditions
CD20+ Follicular Lymphoma
Interventions
Duvelisib, Rituximab, Obinutuzumab
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

NCT00003625
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
cyclosporine, etoposide, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
65
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 2, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

NCT01779167
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Thalidomide, Lenalidomide, Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 2, 2026, 9:49 AM EDT
Not listed Phase 4 Interventional

Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

NCT02237859
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, fruit juice/placebo
Drug · Dietary Supplement
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Recovery Protein Nutrition as a Countermeasure for Anabolic Resistance Following Sleep Loss

NCT06073080
View directory record Official record
Conditions
Sleep, Inadequate
Interventions
Protein Nutrition During Recovery
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 2, 2026, 9:49 AM EDT
Recruiting Phase 2 Interventional

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

NCT07475286
View directory record Official record
Conditions
Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis
Interventions
Cisplatin, Mitomycin C
Drug
Lead sponsor
Mohammad Haroon Asif Choudry
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 2, 2026, 9:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT02953509
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Desensitization in Kidney Transplantation

NCT00908583
View directory record Official record
Conditions
HLA Sensitization
Interventions
plasmapheresis, Bortezomib, Rituximab, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Sep 2, 2026, 9:49 AM EDT
Terminated Phase 3 Interventional Results available

Early Prophylaxis Immunologic Challenge (EPIC) Study

NCT01376700
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 1 Year · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 1 Interventional

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

NCT02728531
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab, Cytarabine, Pegfilgrastim, Leukapheresis, Filgrastim, Autologous stem cell transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 2, 2026, 9:49 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 2, 2026, 9:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protein Eating Patterns and Weight Loss

NCT03202069
View directory record Official record
Conditions
Obesity
Interventions
Even protein, Skewed protein
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
20 Years to 44 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 2, 2026, 9:49 AM EDT